In this issue of Blood, Aubin and colleagues show that IVIg interacted with Fc␥Rs on APCs, resulting in reduced antigen presentation and inhibition of antigenspecific T-cell response. 1 This finding suggests a key role for APCs in IVIg action. R ecent evidence suggests that an essential step in the immunopathology of autoimmune disease (AD) involves antigenpresenting cells (APCs) presenting antigen to antigen-specific CD4 ϩ T helper cells, 2 which, in turn, induce antigen-specific B cells to produce autoantibodies (see figure) . Costimulatory molecules including CD40 and CD154 play an important role in these cellular interactions, which perpetuate the disease. Autoantibodies bind autoantigens to form immune complexes (ICs) that are taken up by APCs via Fc␥ receptors (Fc␥Rs) for antigen processing and presentation, thus maintaining the pathogenic loop. 3, 4 Intravenous immunoglobulin (IVIg) has been used to treat AD for more than 2 decades. The precise mechanism(s) of action is still unclear. 5 In this issue of Blood, Aubin and colleagues 1 provide evidence suggesting that IVIg acts at the level of APC even though they found that IVIg inhibited antigen-specific T-cell and B-cell response. Mice immunized with ovalbumin (OVA) in the presence of IVIg generated reduced numbers of antigenspecific T cells compared with mice immunized with OVA in the absence of IVIg. IVIg treatment during OVA immunization significantly reduced OVA-specific antibody production. These suppressive activities of IVIg were not the result of decreased APC surface expression of MHCII and CD80/ CD86 costimulatory molecules, as previously postulated, but were the consequence of IVIg interfering with IC binding to activating Fc␥Rs expressed on APC.
Three mechanisms have been proposed for the immune suppressive action of IVIg 6 (see figure) in which pathogenic IgG/IC and Fc␥Rs on APC are believed have a role.
Mechanism 1: IVIg competes with IC for activating Fc␥Rs. In this mechanism, high-dose IVIg competes with IC for activating Fc␥Rs on APC surface. 6 Data of Aubin et al 1 would favor this mechanism. First, these investigators showed that 2.4G2, Fc␥RIII-specific monoclonal antibody blocked OVA-IC binding to bone marrow dendritic cells (BM-DCs), used as APC in this study. Second, they found that intact IV IgG inhibited antigen-specific T-cell response but its F(abЈ) fragments did not. Third, BM-DCs from ␥ chain-deficient mice (lacking Fc␥Rs) failed to activate CD4 ϩ T cells in the presence of IC. Altogether, their results suggest that IVIg via its Fc domain competes with IC for binding to activating Fc␥Rs expressed on APCs, consequently reduces APC antigen presentation, and inhibits CD4 ϩ T-cell activation and other downstream immune responses. One reservation in interpreting these data is that monomeric IgG in Mechanism 3: IVIg saturates FcRn binding; FcRn binds pathogenic or nonpathogenic IgGs and protects them from catabolism. The third mechanism postulates that high doses of IVIg saturate the available FcRn binding sites and expose pathogenic autoantibodies, not bound to FcRn, to catabolic removal, thus reducing the amount of circulating autoantibodies. Consistent with this mechanism, Li et al showed that IVIgtreated wild-type mice, but not neonate FcRn-deficient mice, were protected from developing bullous skin disease when the animals were infused with antibodies from patients with pemphigus vulgaris. 8 Mechanism 3, however, is not yet widely accepted because there is some evidence against FcRn having a role in IVIg action. 5 An important drawback in the study of Aubin et al 1 is that they did not use an autoimmune disorder animal model and their findings may not necessarily represent the effects of IVIg in AD. Further studies are required, particularly studies using an autoimmune experimental system. Nevertheless, the findings in this study are helpful in providing insights into the mechanism(s) of IVIg action. If subsequently confirmed by further studies, the knowledge gained may inform development of effective novel therapies for AD, 4 
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In this issue of Blood, Lubenow and colleagues provide the first strong evidence that there is much more besides heparin in triggering the adverse drug reaction, HIT. 1 T o date, research has focused on identifying whether differences in heparin composition influence the risk of immunization against platelet factor 4/heparin (PF4/heparin) complexes, the target of the immune response that characterizes heparin-induced thrombocytopenia (HIT). And, indeed, longer-chain and more sulfated heparins are more likely to trigger immunization and clinically evident HIT. 2 As with any drug reaction, however, only a minority of patients who receive the offending drug are affected. Usually, this is attributed to poorly defined "idiosyncratic" (patientspecific) factors. But in the case of HIT, the perception has grown that there must be additional nondrug, but also nonidiosyncratic, factors that influence immunization risk. The evidence behind this concept has been mostly indirect. For example, surgical patients appear to be more likely to develop HIT than medical patients. 3 This is very different from an "idiosyncratic" reason where Mr X has an inherently higher risk of HIT than Mr Y. Rather, both Mr X and Mr Y would have a higher risk of HIT if they received heparin in the context of surgery, rather than if they received heparin as medical patients. Now, Lubenow et al provide direct evidence that nondrug factors do indeed strongly influence anti-PF4/heparin immunization and HIT risk. They performed a randomized controlled trial comparing 2 types of heparin-unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH) preparation (certoparin)-administered for thromboprophylaxis after trauma. Patients were classified as "major" and "minor" trauma and were systematically evaluated for immunization (various tests for anti-PF4/heparin antibodies) and for HIT (thrombocytopenia and/or thrombosis bearing a temporal relationship to formation of platelet-activating antibodies). In their study, major trauma referred primarily to fractures of the pelvis, femur, tibia, fibula, or humerus; minor trauma to almost everything else (usually, distal upper-extremity, shoulder, and distal lower-extremity fractures).
The table summarizes the frequency of anti-PF4/heparin antibody immunization, as per a combination of immunoassays, categorized by severity of trauma (major, minor) and for type of heparin (UFH, LMWH). The corresponding data for clinical HIT are also shown.
